Your browser doesn't support javascript.
loading
Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers.
Zhang, F; Parayath, N N; Ene, C I; Stephan, S B; Koehne, A L; Coon, M E; Holland, E C; Stephan, M T.
Afiliación
  • Zhang F; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.
  • Parayath NN; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.
  • Ene CI; Department of Neurological Surgery, University of Washington School of Medicine, Seattle, WA, 98195, USA.
  • Stephan SB; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.
  • Koehne AL; Comparative Pathology, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.
  • Coon ME; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.
  • Holland EC; Department of Neurological Surgery, University of Washington School of Medicine, Seattle, WA, 98195, USA.
  • Stephan MT; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.
Nat Commun ; 10(1): 3974, 2019 09 03.
Article en En | MEDLINE | ID: mdl-31481662
Tumor-associated macrophages (TAMs) usually express an M2 phenotype, which enables them to perform immunosuppressive and tumor-promoting functions. Reprogramming these TAMs toward an M1 phenotype could thwart their pro-cancer activities and unleash anti-tumor immunity, but efforts to accomplish this are nonspecific and elicit systemic inflammation. Here we describe a targeted nanocarrier that can deliver in vitro-transcribed mRNA encoding M1-polarizing transcription factors to reprogram TAMs without causing systemic toxicity. We demonstrate in models of ovarian cancer, melanoma, and glioblastoma that infusions of nanoparticles formulated with mRNAs encoding interferon regulatory factor 5 in combination with its activating kinase IKKß reverse the immunosuppressive, tumor-supporting state of TAMs and reprogram them to a phenotype that induces anti-tumor immunity and promotes tumor regression. We further establish that these nanoreagents are safe for repeated dosing. Implemented in the clinic, this immunotherapy could enable physicians to obviate suppressive tumors while avoiding systemic treatments that disrupt immune homeostasis.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: ARN Mensajero / Nanopartículas / Macrófagos / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: ARN Mensajero / Nanopartículas / Macrófagos / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido